Dendreon Jumps 10%

Shares of Dendreon

were sold off hard on Monday after positive data was presented at the American Society of Clinical Oncology conference in Chicago over the weekend showing a high rate of efficacy for a Johnson & Johnson

prostrate cancer drug called Zytiga which is a competitor to DNDN's Provenge treatment. On Tuesday, however, Dendreon shares are bouncing back from the steep losses and were last trading up more than 10% to $6.54. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.